MAVENCLAD
Peakcladribine
NDAORALTABLET
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
synthesis, resulting in depletion of lymphocytes.
Pharmacologic Class:
Purine Antimetabolite
Clinical Trials (5)
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Started Jan 2025
40 enrolled
Acute Monocytic LeukemiaAcute Myeloid Leukemia
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Started Sep 2024
86 enrolled
Hairy Cell Leukemia
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Started Jun 2024
264 enrolled
Generalized Myasthenia Gravis
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
Started Aug 2023
367 enrolled
Multiple Sclerosis
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
Started Aug 2021
116 enrolled
Relapsing-Remitting Multiple Sclerosis
Loss of Exclusivity
LOE Date
Sep 10, 2041
188 months away
Patent Expiry
Sep 10, 2041